Bexagliflozin

Generic Name
Bexagliflozin
Brand Names
Brenzavvy
Drug Type
Small Molecule
Chemical Formula
C24H29ClO7
CAS Number
1118567-05-7
Unique Ingredient Identifier
EY00JF42FV
Background

Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity. In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.

Indication

Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

First Posted Date
2016-05-11
Last Posted Date
2021-05-27
Lead Sponsor
Theracos
Target Recruit Count
426
Registration Number
NCT02769481
Locations
🇪🇸

Research Site 3, Madrid, Spain

🇪🇸

Research Site 2, Oviedo, Spain

🇪🇸

Research Site, Valencia, Spain

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Interventions
First Posted Date
2016-03-22
Last Posted Date
2021-06-28
Lead Sponsor
Theracos
Target Recruit Count
210
Registration Number
NCT02715258
Locations
🇨🇦

Research Site, Pointe-Claire, Quebec, Canada

🇨🇦

Research Site 2, Toronto, Ontario, Canada

🇨🇦

Research Site 1, Toronto, Ontario, Canada

Bexagliflozin Efficacy and Safety Trial

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-09-23
Last Posted Date
2021-07-14
Lead Sponsor
Theracos
Target Recruit Count
1700
Registration Number
NCT02558296
Locations
🇺🇸

Research Site 1079, Hyattsville, Maryland, United States

🇺🇸

Research Site 1219, Somerset, New Jersey, United States

🇺🇸

Research Site 1059, Brooksville, Florida, United States

and more 154 locations
© Copyright 2024. All Rights Reserved by MedPath